The identification of p‐TFCP2L1 and CDK1 expression and co‐expression as predictive markers of cancer‐specific survival could open the prospect of developing p‐TFCP2L1/CDK1‐based immunohistochemical prognostic markers that could be easily applied in the clinic. This evidence concerns the gene TFCP2L1 and cancer.